首页 | 本学科首页   官方微博 | 高级检索  
     


Pharmacodynamic relationship between PCSK9, alirocumab,and LDL-C lowering in the ODYSSEY CHOICE I trial
Affiliation:1. The Sterling Research Group, Cincinnati, OH, USA;2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands;3. Harvard Clinical Research Institute, Boston, MA, USA;4. Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France;5. Virginia Commonwealth University, Richmond, VA, USA;6. Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA;7. Sanofi, Clinical Development, R&D, Montpellier, France;8. Regeneron Pharmaceuticals Inc., Basking Ridge, NJ, USA;9. University of Iowa, Iowa City, IA, USA
Abstract:
><ol class=
  • Download : Download high-res image (475KB)
  • Download : Download full-size image
  • Keywords:Alirocumab  PCSK9  Statin  Pharmacodynamics  Pharmacokinetics
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号